Imbruvica® (ibrutinib) – New indication
August 2, 2017 – The FDA announced the approval of Pharmacyclics’ Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
Download PDF
